I am an academic clinician, interested in regenerative medicine, cardiovascular therapies and research. I am the lead of a stem cell laboratory at Semmelweis Univeristy, in Budapest.
At Semmelweis University, we pride ourselves on being a leading institution in health sciences and medical education. Established in Budapest, we foster a collaborative environment where innovative research and clinical practice converge to improve healthcare outcomes. Our diverse programs cover a wide spectrum of disciplines, including medicine, pharmacy, and health management, enabling us to cultivate skilled professionals equipped to meet the challenges of the evolving healthcare landscape. By partnering with industry stakeholders and engaging in community initiatives, we strive to advance health and wellness both locally and globally.
Gabor is an academic clinician. His clinical background is in medicine with specialisations in Internal Medicine and Cardiology. On the academic side, he received his PhD in cardiovascular biology in 2002 and his DSc on human pluripotent stem cells in heart disease in 2020. He completed a fellowship on cardiac progenitor cells at Harvard in 2006. Between 2007 and 2021, he worked as the lead scientist of the stem cell team at the National Heart and Lung Institute, Imperial College London. In 2023, he was appointed as a Professor of Cardiology at Semmelweis University, Budapest, Hungary. In addition to his clinical background, with over two decades of experience, his focus spans heart failure, cardiomyopathies, stem cell therapies, cardiovascular disease modelling, regenerative medicine, and advanced medical therapies. Gabor joined AstraZeneca as Senior Medical Director in 2022, where he is the medical lead and provides global clinical and translational strategies for various heart failure and cardiomyopathy programs.
Our group studies cardiac microvascular dysfunction in heart failure and dilated cardiomyopathy. Using patient-derived and hiPSC-based endothelial models, and multi-omics, we identify new pathomechanisms, biomarkers, and therapies.